France said that it has teamed with 13 other EU countries to negotiate a lower price for Gilead Sciences' hepatitis C drug Sovaldi, as reported Breitbart Thursday.
Officials in Europe have expressed concern over the drug's 50 000-euro price for a 12-week course of treatment.
"If we accept such a high price, firstly we won't be able to treat everyone and we will also be creating a risk for our social security system, which means for other patients," said France's health minister Marisol Touraine.
"So I launched an initiative...to mobilise all European countries and make sure we join forces to weigh on price negotiations with this US laboratory," Touraine continued, adding "we will therefore negotiate country by country as that's how it's done, but we will exchange information and discuss things between European countries."
Medecins du Monde estimated that the cost of treating about half of all French individuals with hepatitis C would equal the annual budget of Paris' public hospital network.
Earlier this year, Egypt, which has the highest incidence of hepatitis C in the world, negotiated a price of $900 for a 12-week course of treatment.